Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody
After months of searching for a partner for its recently approved cancer drug, Checkpoint Therapeutics has instead secured a buyer. India-headquartered company Sun Pharmaceutical is acquiring the immuno-oncology biotech for $4.10 per share, which equals ...
After months of searching for a partner for its recently approved cancer drug, Checkpoint Therapeutics has instead secured a buyer.
India-headquartered company Sun Pharmaceutical is acquiring the immuno-oncology biotech for $4.10 per share, which equals ...
